机构

• 上海药物研究所 [19]
• 合肥物质科学研究院 [7]

采集方式

• OAI收割 [26]

内容类型

• 期刊论文 [25]
• 会议论文 [1]

发表日期

• 2024 [5]
• 2023 [3]
• 2022 [3]
• 2021 [4]
• 2020 [2]
• 2019 [1]
• 更多

学科主题

筛选

浏览/检索结果: 共26条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 Synthesis and evaluation of hybrid molecules as RIPK1 and HDACs dual inhibitors 期刊论文  OAI收割 JOURNAL OF MOLECULAR STRUCTURE, 2024, 卷号: 1318, 页码: 13 作者:  Tang, Mingze;  Zhou, Xuan;  Shen, Qianqian;  Fang, Chen;  Peng, Xia   |  收藏  |  浏览/下载：12/0  |  提交时间：2024/08/22 Receptor -interacting protein kinase 1  Histone deacetylases  Inhibitor  Molecular dynamics (MD) simulation  ADMET analysis   Design and synthesis of pyridazin-4-one derivatives as necroptosis inhibitors 期刊论文  OAI收割 ARCHIV DER PHARMAZIE, 2024, 页码: 16 作者:  An, Yuxiang;  Peng, Xia;  Wang, Tianchen;  Liu, Kaiyuan;  Feng, Dazhi   |  收藏  |  浏览/下载：8/0  |  提交时间：2024/12/25 inhibitor  pharmacokinetic study  pyridazin-4-one  receptor-interacting protein kinase 1  selectivity   Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 卷号: 9, 期号: 1, 页码: 17 作者:  Zhang, Tao;  Pan, Zilu;  Gao, Jing;  Wu, Qingqing;  Bai, Gang   |  收藏  |  浏览/下载：16/0  |  提交时间：2024/10/21 Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial 期刊论文  OAI收割 CANCER COMMUNICATIONS, 2024 作者:  Zuo, Jing;  Duan, Wei;  Zhao, Mingxuan;  Chen, Zhendong;  Lin, Jie   |  收藏  |  浏览/下载：3/0  |  提交时间：2024/11/22 A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy 期刊论文  OAI收割 CANCER COMMUNICATIONS, 2024, 页码: 5 作者:  Liu, Yingqiang;  Tong, Linjiang;  Zhang, Mengge;  Zhang, Qi;  Liu, Qiupei   |  收藏  |  浏览/下载：37/0  |  提交时间：2024/03/13 Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4748-4764 作者:  Liu, Yingqiang;  Zhan, Zhengsheng;  Kang, Zhuang;  Li, Mengyuan;  Lv, Yongcong   |  收藏  |  浏览/下载：23/0  |  提交时间：2024/01/26 Small molecule inhibitor  Tumor microenvironment  Immune-checkpoint  immune-deficient mouse models  including temozolomide (TMZ) insensitive tumors. Notably   Structure-based drug discovery of novel fused- pyrazolone carboxamide derivatives as potent and selective AXL inhibitors 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4918-4933 作者:  Fang, Feifei;  Dai, Yang;  Wang, Hao;  Ji, Yinchun;  Liang, Xuewu   |  收藏  |  浏览/下载：23/0  |  提交时间：2024/01/26 derivatives  Antitumor drug development  Potential AXL inhibitor  Antitumor activity  Structure-based drug design  Fused-pyrazolone carboxamide   Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：120/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor 期刊论文  OAI收割 THORACIC CANCER, 2022 作者:  Wang, Wenxian;  Wang, Qian;  Xu, Chunwei;  Li, Ziming;  Song, Zhengbo   |  收藏  |  浏览/下载：57/0  |  提交时间：2022/12/23 checkpoint inhibitor pneumonitis  Chinese experts consensus  immune checkpoint inhibitor-related adverse effects   Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China 期刊论文  OAI收割 THORACIC CANCER, 2022 作者:  Xu, Chunwei;  Si, Lu;  Wang, Wenxian;  Li, Ziming;  Song, Zhengbo   |  收藏  |  浏览/下载：62/0  |  提交时间：2022/12/22 fusion  precision medicine  solid tumor  targeted therapy  tyrosine receptor kinase